Tevogen Bio HoldingsTVGN
TVGN
About: Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Employees: 17
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
67% more capital invested
Capital invested by funds: $2.49M [Q4 2024] → $4.16M (+$1.67M) [Q1 2025]
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
16% more funds holding
Funds holding: 45 [Q4 2024] → 52 (+7) [Q1 2025]
0.82% more ownership
Funds ownership: 1.38% [Q4 2024] → 2.2% (+0.82%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
880%
upside
Avg. target
$10
880%
upside
High target
$10
880%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 880%upside $10 | Buy Maintained | 18 Jun 2025 |
Financial journalist opinion
Based on 7 articles about TVGN published over the past 30 days
Neutral
GlobeNewsWire
8 hours ago
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.
Neutral
GlobeNewsWire
2 days ago
Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House's release of “Winning the Race: America's AI Action Plan”, issued July 23, 2025. The Company applauds the federal government's emphasis on establishing domain-specific standards, regulatory sandboxes (aka AI Centers of Excellence), and stakeholder convenings led by The National Institute of Standards and Technology to build trust, governance, and productivity in healthcare AI.
Neutral
GlobeNewsWire
1 week ago
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."
Neutral
GlobeNewsWire
1 week ago
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company's cell therapy manufacturing operations.
Neutral
GlobeNewsWire
2 weeks ago
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
WARREN, N.J., July 16, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that following the completion and deployment of the alpha version of PredicTcell™, a proprietary AI-driven target discovery platform, the Company now plans to expand Tevogen.AI to include patient data against identified targets.
Neutral
GlobeNewsWire
2 weeks ago
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
WARREN, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, in collaboration with Microsoft (Nasdaq: MSFT) and Databricks, has successfully built the alpha version of its foundational PredicTcell™ model.
Neutral
GlobeNewsWire
2 weeks ago
Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
WARREN, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the completion and official opening of its fully functional, newly expanded corporate headquarters in Warren, New Jersey. The build-out and first-year operating costs were personally gifted by Founder and Chief Executive Officer Ryan Saadi, M.D., M.P.H., resulting in no expense to the Company or its shareholders.
Neutral
GlobeNewsWire
4 weeks ago
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and Chief Executive Officer, Ryan Saadi, M.D., M.P.H., has personally contributed $500,000 towards the build-out and first-year operating costs of Tevogen's new corporate headquarters in Warren, New Jersey.
Neutral
GlobeNewsWire
1 month ago
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associated lymphomas.
Neutral
GlobeNewsWire
1 month ago
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency. Tevogen.AI, strengthened by its partnership with Microsoft, continues to expand.
Charts implemented using Lightweight Charts™